Management of Dry Eye Toxicity After Treatment With 177Lu-PSMA-617 Radioligand Therapy

被引：1
|
作者：
Pepin, Abigail [1 ]
Lee, Vivian [2 ]
O'Brien, Sophia [3 ]
Mulugeta, Philipose [3 ]
Taunk, Neil K. [1 ]
机构：
[1] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Dept Ophthalmol, Philadelphia, PA USA
[3] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA USA
来源：
PRACTICAL RADIATION ONCOLOGY | 2024年 / 14卷 / 04期
关键词：
SALIVARY; GLANDS;
D O I：
10.1016/j.prro.2024.04.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Treatment options for patients with metastatic castration-resistant prostate cancer include use of radioligand therapy with 177LuPSMA-617. 177Lu-PSMA-617 is used to target prostate cancer cells selectively by targeting prostate specific membrane antigen (PSMA); however, PSMA is also expressed on lacrimal glands among other tissues. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 3 dry eye event with concomitant blepharitis after administration of 177Lu-PSMA-617. The patient was managed with neomycin-polymyxin-dexamethasone 3.5-10000-0.1 ophthalmic suspension, artificial tears, lubricating ointments, lid scrubs, and oral antihistamines. (c) 2024 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：301 / 304
页数：4
相关论文
共 50 条
  • [31] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Rahbar, Kambiz
    Boegeman, Martin
    Yordanova, Anna
    Eveslage, Maria
    Schaefers, Michael
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (02) : 243 - 246
  • [32] Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Becker, Anja
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fisang, Christian
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [33] Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
    Jadvar, Hossein
    Iravani, Amir
    Bodei, Lisa
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1851 - 1854
  • [34] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [35] German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Haberkorn, Uwe
    Schaefers, Michael
    Essler, Markus
    Baum, Richard P.
    Kulkarni, Harshad R.
    Schmidt, Matthias
    Drzezga, Alexander
    Bartenstein, Peter
    Pfestroff, Andreas
    Luster, Markus
    Luetzen, Ulf
    Marx, Marlies
    Prasad, Vikas
    Brenner, Winfried
    Heinzel, Alexander
    Mottaghy, Felix M.
    Ruf, Juri
    Meyer, Philipp Tobias
    Heuschkel, Martin
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang Peter
    Krause, Bernd Joachim
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) : 85 - 90
  • [36] 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
    Braeuer, Axel
    Grubert, Lena Sophie
    Roll, Wolfgang
    Schrader, Andres Jan
    Schaefers, Michael
    Boegemann, Martin
    Rahbar, Kambiz
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1663 - 1670
  • [37] Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Kambiz Rahbar
    Martin Bögeman
    Anna Yordanova
    Maria Eveslage
    Michael Schäfers
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 243 - 246
  • [38] Myelotoxicity after Treatment with 177Lu-PSMA-617 in Patients with Metastatic Prostate Cancer
    Groener, D.
    Baumgarten, J.
    Davis, K.
    Happel, C.
    Mader, N.
    Ngoc, C. Nguyen
    Wichert, J.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S695
  • [39] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [40] Administration of 177Lu-PSMA-617 as Compared to 177Lu-Dotatate
    Patel, P.
    McCall, K.
    MEDICAL PHYSICS, 2022, 49 (06) : E811 - E812
12345